Tags

Type your tag names separated by a space and hit enter

[Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey].
Med Klin (Munich). 2007 Nov 15; 102(11):888-92.MK

Abstract

BACKGROUND AND PURPOSE

In many patients with irritable bowel syndrome (IBS), one symptom is predominant (e.g., diarrhea, constipation, meteorism, or alternating stool consistency). For IBS therapy, probiotic drugs such as Mutaflor (active ingredient: Escherichia coli strain Nissle 1917 [EcN]) are also being used. A systematic survey on the efficacy and safety of EcN in different IBS subgroups is still missing.

PATIENTS AND METHODS

In a gastroenterologic outpatient practice, results of 150 IBS patients treated with EcN were evaluated retrospectively. Most IBS patients enrolled belonged to the subgroups "diarrhea", "meteorism", and "alternating stool consistency".

RESULTS

Regarding the diarrhea subgroup, not only a statistically significant improvement in stool frequency was observed, but also a marked improvement in concomitant symptoms such as abnormal urge, flatulence, and abdominal fullness. These complaints improved under EcN therapy in the other IBS subgroups as well, so that efficacy was assessed as "good to very good" in 73.4% of all cases. Tolerance to treatment was "good to very good" in 97.9% of the cases.

CONCLUSION

The results point to the possibility of EcN being a therapeutic option for patients of various IBS subgroups which is almost free of side effects.

Authors+Show Affiliations

Praxis für Innere Medizin/Gastroenterologie, Münsterstrasse 18 (Cassiusbastei), 53111, Bonn, Germany. info@gastroenterologie-bonn.deNo affiliation info available

Pub Type(s)

Journal Article

Language

ger

PubMed ID

17992479

Citation

Plassmann, Dominik, and Hildegard Schulte-Witte. "[Treatment of Irritable Bowel Syndrome With Escherichia Coli Strain Nissle 1917 (EcN): a Retrospective Survey]." Medizinische Klinik (Munich, Germany : 1983), vol. 102, no. 11, 2007, pp. 888-92.
Plassmann D, Schulte-Witte H. [Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey]. Med Klin (Munich). 2007;102(11):888-92.
Plassmann, D., & Schulte-Witte, H. (2007). [Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey]. Medizinische Klinik (Munich, Germany : 1983), 102(11), 888-92.
Plassmann D, Schulte-Witte H. [Treatment of Irritable Bowel Syndrome With Escherichia Coli Strain Nissle 1917 (EcN): a Retrospective Survey]. Med Klin (Munich). 2007 Nov 15;102(11):888-92. PubMed PMID: 17992479.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey]. AU - Plassmann,Dominik, AU - Schulte-Witte,Hildegard, PY - 2007/02/28/received PY - 2007/09/05/accepted PY - 2007/11/10/pubmed PY - 2008/2/1/medline PY - 2007/11/10/entrez SP - 888 EP - 92 JF - Medizinische Klinik (Munich, Germany : 1983) JO - Med Klin (Munich) VL - 102 IS - 11 N2 - BACKGROUND AND PURPOSE: In many patients with irritable bowel syndrome (IBS), one symptom is predominant (e.g., diarrhea, constipation, meteorism, or alternating stool consistency). For IBS therapy, probiotic drugs such as Mutaflor (active ingredient: Escherichia coli strain Nissle 1917 [EcN]) are also being used. A systematic survey on the efficacy and safety of EcN in different IBS subgroups is still missing. PATIENTS AND METHODS: In a gastroenterologic outpatient practice, results of 150 IBS patients treated with EcN were evaluated retrospectively. Most IBS patients enrolled belonged to the subgroups "diarrhea", "meteorism", and "alternating stool consistency". RESULTS: Regarding the diarrhea subgroup, not only a statistically significant improvement in stool frequency was observed, but also a marked improvement in concomitant symptoms such as abnormal urge, flatulence, and abdominal fullness. These complaints improved under EcN therapy in the other IBS subgroups as well, so that efficacy was assessed as "good to very good" in 73.4% of all cases. Tolerance to treatment was "good to very good" in 97.9% of the cases. CONCLUSION: The results point to the possibility of EcN being a therapeutic option for patients of various IBS subgroups which is almost free of side effects. SN - 0723-5003 UR - https://www.unboundmedicine.com/medline/citation/17992479/[Treatment_of_irritable_bowel_syndrome_with_Escherichia_coli_strain_Nissle_1917__EcN_:_a_retrospective_survey]_ L2 - https://dx.doi.org/10.1007/s00063-007-1116-2 DB - PRIME DP - Unbound Medicine ER -